Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 764532 PET Imaging Trial in SCLC and Neuroendocrine Carcinoma
NCT05963867Phase 1Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2024
- Primary completion
- Dec 2026
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of obrixtamig in Small Cell Lung Cancer (SCLC) and Neuroendocrine neoplasm (NEN) (2 cohorts), sponsored by Boehringer Ingelheim. Primary endpoint: Mean relative change from baseline of [89Zr]Zr-BI 764532 tumour-to-plasma ratios up to 35 days. Started Aug 2024; status: recruiting.
02
Drugs
obrixtamig
03
Conditions
Small Cell Lung Cancer (SCLC)Neuroendocrine neoplasm (NEN)
Beyond the preview
Go deeper on NCT05963867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05963867.